ACOS and Avedro Announce Initiation of a Phase 3 Study On Accelerated Corneal Cross-Linking – Yahoo Finance

Each of the 100 clinical sites will use Avedro’s KXL™ System and VibeX™ (riboflavin ophthalmic solution) to treat all patients enrolled in the study. Stephen G. Slade, MD, President of ACOS said, “In the absence of any FDA approval for …